Article

Radiotherapy for subfoveal CNV has early, but not durable benefits

Author(s):

Cheryl Guttman

Fort Lauderdale, FL-High-dose (5 3 4-Gy fractions; 6 MeV) external-beam radiation therapy has only a modest and very short-lived benefit in the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), according to an interim analysis of data from the Age-Related Macular Degeneration Radiotherapy Trial (AMDRT).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada
June 18th 2025

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Pathways for better care: When patients and providers move in sync
June 18th 2025

Pathways for better care: When patients and providers move in sync

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/Nadiia) Mount Sinai’s NYEE unveils Center for Refractive Solutions
June 17th 2025

Mount Sinai’s NYEE unveils Center for Refractive Solutions

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease
June 17th 2025

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease

© 2025 MJH Life Sciences

All rights reserved.